natgillin/translations-raw huggingface dataset:
Nekrotiserende fasciitis, som regel sekundært til sårhelingskomplikationer, gastrointestinal perforation eller fisteldannelse (sjælden) (se også pkt. 
Infections and infestations Necrotising fasciitis, usually secondary to wound healing complications, gastrointestinal perforation or fistula formation (rare) (see also section 4.4)
For yderligere information henvises til Tabel 3 ”Bivirkninger rapporteret post-marketing”. 
For further information please refer to table 3 “Adverse reactions reported in post-marketing setting”.
Der er ikke observeret klinisk relevante interaktioner af bevacizumab på farmakokinetikken af samtidig administreret interferon alfa 2a, erlotinib (og den aktive metabolit OSI-420) eller af følgende kemoterapeutika: irinotecan (og den aktive metabolit SN38), capecitabin, oxaliplatin (bestemt ved måling af frit og totalt platin) og cisplatin. 
No clinically relevant interaction of bevacizumab was observed on the pharmacokinetics of co-administered interferon alfa 2a, erlotinib (and its active metabolite OSI-420), or the chemotherapies irinotecan (and its active metabolite SN38), capecitabine, oxaliplatin (as determined by measurement of free and total platinum), and cisplatin.
INDHOLD ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER 100 mg/4 ml 
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 100 mg/4 mL
Hazard ratio blev estimeret ud fra Cox proportionelle hazard modeller stratificeret efter varighed af platinfri periode før inklusion i studiet per eCRF (electronic case report form) og sekundær kirurgisk tumorreduktionsstatus Ja/Nej. 
Hazard ratio was estimated from Cox proportional hazards models stratified by the duration of platinum free-interval prior to enrolling onto this study per eCRF (electronic case report form) and secondary surgical debulking status Yes/No (Yes = randomised to undergo cytoreduction or randomised to not undergo cytoreduction; No = not a candidate or did not consent to cytoreduction).
INDHOLD ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER 400 mg/16 ml 
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 400 mg/16 mL
Det primære endepunkt var progressionsfri overlevelse og de sekundære endepunkter for studiet inkluderede længden af den samlede overlevelse. 
The primary endpoint was progression-free survival, secondary endpoints for the trial included the duration of overall survival.
• Gastrointestinale perforationer (se pkt. 
• Gastrointestinal perforations (see section 4.4).
Der blev randomiseret 813 patienter til behandling med IFL + placebo (arm 1) eller IFL + bevacizumab (5 mg/kg hver 2. uge, arm 2). 
Eight hundred and thirteen patients were randomised to receive IFL + placebo (Arm 1) or IFL + bevacizumab (5 mg/kg every 2 weeks, Arm 2).
Tidligere strålebehandling er en væsentlig risikofaktor for udvikling af gastrointestinalevaginale fistler, og alle patienter, som fik gastrointestinale-vaginale fistler, havde tidligere fået strålebehandling. 
Prior radiation is a major risk factor for the development of GI-vaginal fistulae and all patients with GI-vaginal fistulae had a history of prior radiation.
Sårhelingskomplikationera,b Palmoplantar erytrodysæstesi syndrom 
Wound healing complicationsa,b, Palmar-plantar erythrodysaesthesia syndrome
Hypertensionb,d Tromboemboli (venøs)b,d 
Hypertensionb,d, Thromboemboli sm (venous)b,d
Resultaterne for behandling med bevacizumab og førsøgsbehandling fra den primære analyse og followup-analysen er præsenteret i tabel 24 og 25. 
Results from the primary analysis and the follow-up analysis are presented by bevacizumab treatment and by trial treatment in table 24 and 25, respectively.
Effekten og sikkerheden af bevacizumab i kombination med kemoterapi (paclitaxel og cisplatin eller paclitaxel og topotecan) i behandlingen af patienter med persisterende, recidiverende eller metastatisk cervixkarcinom blev evalueret i studiet GOG-0240, et randomiseret, 4-armet, åbent fase III multicenterstudie. 
The efficacy and safety of bevacizumab in combination with chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan) in the treatment for patients with persistent, recurrent or metastatic carcinoma of the cervix was evaluated in study GOG-0240, a randomised, four-arm, open label, multicentre phase III trial.
Resultaterne er præsenteret i tabel 11. 
Results are presented in table 11.
MVASI vil blive givet i kombination med kemoterapibehandling, der indeholder fluoropyrimidin. 
MVASI will be administered in combination with chemotherapy treatment containing a fluoropyrimidine medicine.
Hypertension blev generelt adækvat behandlet med orale antihypertensiva som f.eks. ACE-hæmmere, diuretika og calciumantagonister. 
Hypertension was generally adequately controlled with oral anti-hypertensives such as angiotensinconverting enzyme inhibitors, diuretics and calcium-channel blockers.
I et retrospektivt studie på en enkelt institution blev 12 konsekutive børn (2005-2008) med recidiverende eller progredierende høj-grads-gliom (3 med WHO grad IV, 9 med grad III) behandlet med bevacizumab (10 mg/kg) og irinotecan (125 mg/m²) hver anden uge. 
In a retrospective single institution series, 12 consecutive (2005 to 2008) children with relapsed or progressive high-grade glioma (3 with WHO grade IV, 9 with grade III) were treated with bevacizumab (10 mg/kg) and irinotecan (125 mg/m2) every 2 weeks.
Effektresultater fra studie BO17705 
Efficacy results for trial BO17705
Studie E2100 var et åbent, randomiseret, aktivt kontrolleret, multicenter klinisk studie til evaluering af bevacizumab i kombination med paclitaxel til lokalt recidiverende eller metastatisk brystkræft hos patienter, som ikke tidligere havde fået kemoterapi for lokalt recidiverende og metastatisk sygdom. 
Trial E2100 was an open-label, randomised, active-controlled, multicentre clinical trial evaluating bevacizumab in combination with paclitaxel for locally recurrent or metastatic breast cancer in patients who had not previously received chemotherapy for locally recurrent and metastatic disease.
LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) MVASI 25 mg/ml koncentrat, sterilt bevacizumab i.v. 
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION MVASI 25 mg/mL sterile concentrate bevacizumab
Patienter med histologisk bekræftet metastatisk kolorektalkræft og sygdomsprogression blev randomiseret 1:1 indenfor 3 måneder efter seponering af 1.linje bevacizumab-behandling og fik fluoropyrimidin/oxaliplatin- eller fluoropyrimidin/irinotecan-baseret kemoterapi (kemoterapi ændret afhængigt af 1.linje-kemoterapi) med eller uden bevacizumab. 
Patients with histologically confirmed mCRC and disease progression were randomised 1:1 within 3 months after discontinuation of bevacizumab first-line therapy to receive fluoropyrimidine/oxaliplatin- or fluoropyrimidine/irinotecan-based chemotherapy (chemotherapy switched depending on first-line chemotherapy) with or without bevacizumab.
Sådan skal du bruge MVASI 
How to use MVASI
• en blodprop i arterierne, 
• a blood clot in your arteries,
10 mg/kg hver 2. uge. 
10 mg/kg every 2 weeks.
CHF-bivirkninger af grad 3 eller højere var lidt hyppigere hos patienter i behandling med bevacizumab i kombination med kemoterapi end hos patienter, som blev behandlet med kemoterapi alene. 
CHF grade 3 or higher reactions were somewhat more frequent among patients receiving bevacizumab in combination with chemotherapy than in patients receiving chemotherapy alone.
Patienter, som tidligere var behandlet med bevacizumab eller tidligere havde fået systemisk anticancerbehandling for ovariecancer (f.eks. kemoterapi, behandling med monoklonale antistoffer, behandling med tyrosinkinasehæmmer eller hormonbehandling), eller som tidligere havde fået strålebehandling af abdomen eller bækken, blev ekskluderet fra studiet. 
Patients who had received prior therapy with bevacizumab or prior systemic anti-cancer therapy for ovarian cancer (e.g. chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy, or hormonal therapy) or previous radiotherapy to the abdomen or pelvis were excluded from the study.
FOLFOX-4 eller XELOX + bevacizumab (n = 699) 
FOLFOX-4 or XELOX + bevacizumab (n = 699)
MVASI skal seponeres hos patienter med livstruende (grad 4) tromboemboliske bivirkninger, herunder lungeemboli (NCI-CTCAE v. 3). 
MVASI should be discontinued in patients with life-threatening (grade 4) thromboembolic reactions, including pulmonary embolism (NCI-CTCAE v.3).
Patienter, som tidligere har oplevet en venøs tromboembolisk bivirkning, kan have en højere risiko for fornyet hændelse, hvis de får bevacizumab i kombination med kemoterapi, end hvis de får kemoterapi alene. 
Patients who have experienced a venous thromboembolic reaction may be at higher risk for a recurrence if they receive bevacizumab in combination with chemotherapy versus chemotherapy alone.
Brugen af bevacizumab er blevet forbundet med alvorlige tilfælde af fistler, herunder også letale tilfælde. 
Bevacizumab use has been associated with serious cases of fistulae including reactions resulting in death.
• åbent sår eller hul i slimhinderne i maven eller tyndtarmen (symptomer kan være mavesmerter, oppustethed, sort tjæreagtig afføring eller blod i afføringen eller blod i opkast), 
• an open sore or hole in the lining of the stomach or small intestine (the signs may include abdominal pain, feeling bloated, black tarry stools or blood in your stools (faeces) or blood in your vomit),
Overfølsømhed Infusionsreaktionera,b,c 
Infusion reactionsa,b,c
Tilføjelse af bevacizumab til RT/T viste ikke kliniske fordele i studie BO25041 hos 60 evaluerbare børn med nyligt diagnosticeret supratentorielt eller infratentorielt cerebellært eller pedunkulært høj-grads-gliom (se pkt. 
Addition of bevacizumab to RT/T did not demonstrate clinical benefit in study BO25041 in 60 evaluable children patients with newly diagnosed supratentorial or infratentorial cerebellar or peduncular high-grade glioma (HGG) (see section 4.2 for information on paediatric use).
Grad 4 proteinuri (nefrotisk syndrom) blev set hos op til 1,4 % af de patienter, som blev behandlet med bevacizumab. 
Grade 4 proteinuria (nephrotic syndrome) was seen in up to 1.4% of patients treated with bevacizumab.
Tilfælde af osteonekrose af kæben (ONJ) er blevet rapporteret hos patienter behandlet med bevacizumab, hvoraf de fleste tilfælde forekom hos patienter, der havde kendte risikofaktorer for ONJ, navnlig eksponering for intravenøse bisfosfonater og/eller en anamnese med tandsygdomme, som krævede invasive tandprocedurer (se også pkt. 
Cases of osteonecrosis of the jaw (ONJ) have been reported in patients treated with bevacizumab, most of which occurred in patients who had identified risk factors for ONJ, in particular exposure to intravenous bisphosphonates and/or a history of dental disease requiring invasive dental procedures (see also section 4.4) Cases of non-mandibular osteonecrosis have been observed in bevacizumab-treated paediatric patients (see section 4.8, Paediatric population)
Der bør udvises forsigtighed, når patienter med klinisk signifikant hjertesygdom, såsom hjertekarsygdom eller kongestiv hjerteinsufficiens, behandles med bevacizumab. 
Caution should be exercised when treating patients with clinically significant cardiovascular disease such as pre-existing coronary artery disease, or congestive heart failure with bevacizumab.
Ingen bevacizumab 
No bevacizumab
Patienter med tromboemboliske bivirkninger ≤ grad 3 (NCI-CTCAE v. 3) skal monitoreres nøje. 
Patients with thromboembolic reactions ≤ grade 3 need to be closely monitored (NCI-CTCAE v.3).
Placebo eller bevacizumab 
Placebo or bevacizumab
Når MVASI administreres i kombination med topotecan (givet på dag 1-5 hver 3. uge), er den anbefalede MVASI-dosis 15 mg/kg kropsvægt en gang hver 3. uge som intravenøs infusion. 
When MVASI is administered in combination with topotecan (given on days 1-5, every 3 weeks), the recommended dose of MVASI is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.
Hypertensiv encefalopatia 
Hypertensive encephalopathya
Patienterne blev randomiseret til paclitaxel alene (90 mg/m indgivet intravenøst som 1-times infusion en gang ugentligt i tre ud af fire uger) eller i kombination med bevacizumab (10 mg/kg indgivet som intravenøs infusion hver 2. uge). 
Patients were randomised to paclitaxel alone (90 mg/m2 / IV over 1-hour once weekly for three out of four weeks) or in combination with bevacizumab (10 mg/kg IV infusion every two weeks).
Aneurismer og arterielle dissektioner (se pkt. 
Aneurysms and artery dissections (see section 4.8)
Patienter, behandlet med bevacizumab for persisterende, recidiverende eller metastatisk cervixcancer, har en øget risiko for dannelse af fistler mellem vagina og alle dele af mave-tarmkanalen (gastrointestinalevaginale fistler). 
Patients treated for persistent, recurrent, or metastatic cervical cancer with bevacizumab are at increased risk of fistulae between the vagina and any part of the GI tract (Gastrointestinal-vaginal fistulae).
Bevacizumabs sikkerhed og virkning ved behandling af recidiverende epitelial ovariecancer, tubacancer og primær peritonealcancer blev undersøgt i tre fase III-studier (AVF4095g, MO22224 og GOG-0213) hos forskellige patientpopulationer og med forskellige kemoterapiregimer. 
The safety and efficacy of bevacizumab in the treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer was studied in three phase III trials (AVF4095g, MO22224 and GOG-0213) with different patient populations and chemotherapy regimens.
Studie BO17704 har vist, at bevacizumab givet som både 7,5 mg/kg legemsvægt hver 3. uge og 15 mg/kg legemsvægt hver 3. uge øger progressionsfri overlevelse og responsraten. 
Trial BO17704 has demonstrated that both 7.5 mg/kg/q3wk and 15 mg/kg/q3wk bevacizumab doses increase progression-free survival and response rate.
Studie JO25567 var et randomiseret, åbent fase II multicenterstudie, gennemført i Japan, for at vurdere effekten og sikkerheden af bevacizumab, som tillæg til erlotinib, hos patienter med ikke-planocellulær NSCLC med EGFR-aktiverende mutationer (exon 19-deletion eller exon 21L858R-mutation), som ikke tidligere havde fået systemisk behandling af grad IIIB/IV- eller recidiverende sygdom. 
Study JO25567 was a randomised, open-label, multi-centre phase II study conducted in Japan to evaluate the efficacy and safety of bevacizumab used in addition to erlotinib in patients with nonsquamous NSCLC with EGFR activating mutations (exon 19 deletion or exon 21 L858R mutation) who had not received prior systemic therapy for stage IIIB/IV or recurrent disease.
I studie AVF3694g var hyppigheden af CHF (alle grader) i antracyklin + bevacizumab-armen (6,2 %) endvidere sammenlignelig med hyppigheden i antracyklin + placebo-armen (6,0 %). 
In addition, in study AVF3694g the incidences of all grade CHF were similar between the anthracycline + bevacizumab (6.2%) and the anthracycline + placebo arms (6.0%).
• Det er muligt, at MVASI kan forårsage allergiske og/eller infusionsrelaterede reaktioner. 
• It is possible that MVASI can cause hypersensitivity and/or infusion reactions (reactions related to your injection of the medicine).
Objektiv responsrate1 
Objective response rate1
Hvis du holder op med at få MVASI 
If you stop treatment with MVASI
Ifølge en uafhængig evalueringskomité var forskellen i objektiv responsrate 18 % (konfidensinterval: 0,6 %; 35,3 %) mellem de to behandlingsarme blandt de få patienter, der havde evaluerbare tumorer ved baseline samt en bekræftet respons ved tidligere lokal behandling: 27/75 patienter (36,0 %; 95 % konfidensinterval: 25,2 %; 47,9 %) i kemoterapi-armen og 34/63 patienter (54,0 %; 95 % konfidensinterval: 40,9 %; 66,6 %) i kemoterapi + bevacizumab-armen. 
The difference in ORR per independent central review was 18% (CI: 0.6%, 35.3%) between the two treatment arms in the few patients who had evaluable tumour at baseline and had a confirmed response prior to receiving any local therapy: 27/75 patients (36.0%, 95% CI: 25.2%, 47.9%) in the chemo arm and 34/63 patients (54.0%, 95% CI: 40.9%, 66.6%) in the BV + chemo arm.
Både bevacizumabdoser svarende til 5 mg/kg/uge og 2,5 mg/kg/uge viste statistisk signifikant fordel med hensyn til samlet overlevelse (hazard ratio 0,751 i E3200-studiet, hazard ratio 0,81 i ML18147-studiet) og progressionfri overlevelse (hazard ratio 0,518 i E3200-studiet, hazard ratio 0,68 i ML18147-studiet). 
Both the 5 mg/kg/week and 2.5 mg/kg/week equivalent doses of bevacizumab provided a statistically significant benefit with regards to OS (HR 0.751 in study E3200; HR 0.81 in study ML18147) and PFS (HR 0.518 in study E3200; HR 0.68 in study ML18147).
Kombination med platin- eller taxanbaserede terapier (se pkt. 
Combination with platinum- or taxane-based therapies (see sections 4.4 and 4.8)
Osteonekrose af kæbena,b Ikke-mandibulær osteonekrosea,f 
Osteonecrosis of the jawa,b, Nonmandibular osteonecrosisa,
Posteriort reversibelt encefalopati-syndrom (PRES) (sjælden) (se også pkt. 
Posterior Reversible Encephalopathy Syndrome (PRES) (rare) (see also section 4.4)
MVASI er, i kombination med paclitaxel, indiceret til 1.-linjebehandling af voksne patienter med metastatisk brystkræft. 
MVASI in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer.
MVASI er, i kombination med interferon alfa-2a, indiceret til 1.-linjebehandling af voksne patienter med fremskreden og/eller metastatisk renalcellekarcinom. 
MVASI in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.
Alvorlige bivirkninger, som kan være almindelige (kan påvirke op til 1 patient ud af 10), omfatter: 
Severe side effects, which may be common (may affect up to 1 in 10 people), include:
Behandling af platinfølsom recidiverende sygdom: MVASI administreres enten sammen med carboplatin og gemcitabin i 6 og op til 10 behandlingsserier eller sammen med carboplatin og paclitaxel i 6 og op til 8 behandlingsserier, efterfulgt af fortsat behandling med MVASI som monoterapi indtil sygdomsprogression. 
Treatment of platinum-sensitive recurrent disease: MVASI is administered in combination with either carboplatin and gemcitabine for 6 cycles and up to 10 cycles or in combination with carboplatin and paclitaxel for 6 cycles and up to 8 cycles, followed by continued use of MVASI as single agent until disease progression.
• Arteriel tromboemboli (se pkt. 
• Arterial thromboembolism (see section 4.4).
Hver ml koncentrat indeholder 25 mg bevacizumab svarende til 1,4 til 16,5 mg/ml efter foreskreven fortynding. 
Each mL of concentrate contains 25 mg of bevacizumab, corresponding to 1.4 to 16.5 mg/mL when diluted as recommended.
Hazard ratio for progressionsfri overlevelse var 0,47 (95 % konfidensinterval: 0,35; 0,62) og 0,45 (95 % konfidensinterval: 0,31; 0,67) for henholdsvis undergruppe < 65 år og ≥ 65 år. 
The HR for PFS was 0.47 (95% CI: 0.35, 0.62) and 0.45 (95% CI: 0.31, 0.67) for the < 65 and ≥ 65 subgroups, respectively.
score på 0 ved baseline, 43 % en GOG PS-score på 1 og 7 % en GOG PS score på 2. 
Overall approximately 50% of patients had a GOG PS of 0 at baseline, 43% a GOG PS score of 1, and 7% a GOG PS score of 2.
Sekundære PFS analyser, baseret på responsvurderinger fra ”on-treatment”populationen, bekræftede den signifikante, superiore, kliniske effekt for patienter, behandlet med bevacizumab (analyser vist i tabel 7). 
Secondary PFS analyses, based on ‘on-treatment'-based response assessments, confirmed the significantly superior clinical benefit for patients treated with bevacizumab (analyses shown in table 7), consistent with the statistically significant benefit observed in the pooled analysis.
MVASI bruges også hos voksne til behandling af fremskreden ikke-småcellet lungekræft. 
MVASI is also used for the treatment of adult patients with advanced non-small cell lung cancer.
EGFR-mutationsstatus blev bestemt for hver patient før patientscreening, og 154 patienter blev randomiseret til at få enten erlotinib + bevacizumab (oralt erlotinib 150 mg dagligt + bevacizumab [i.v. 
EGFR mutation status was determined for each patient prior to patient screening and 154 patients were randomised to receive either erlotinib + bevacizumab (erlotinib 150 mg oral daily + bevacizumab [15 mg/kg IV every 3 weeks]) or erlotinib monotherapy (150 mg oral daily) until disease progression (PD) or unacceptable toxicity.
af de inkluderede patienter. 
Patients included in analysis
Studiet sammenlignede effekten af at tilføje bevacizumab til carboplatin plus gemcitabin-kemoterapi og fortsætte med bevacizumab i monoterapi til progression, med behandling med carboplatin plus gemcitabin alene. 
The study compared the effect of adding bevacizumab to carboplatin and gemcitabine chemotherapy and continuing bevacizumab as a single agent to progression, to carboplatin and gemcitabine alone.
30-90 min Dag 1, før XELOX, hver 3. uge 
7.5 mg/kg IV 30-90 min Day 1, prior to XELOX, q 3 weeks
MVASI bliver givet sammen med paclitaxel og cisplatin eller med paclitaxel og topotecan til patienter, som ikke kan få platin. 
MVASI will be administered in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy.
(p-værdi = 0,8910) 
(p-value = 0.8910)
Alvorlige bivirkninger, som kan være meget almindelige (kan påvirke flere end 1 patient ud af 10), omfatter: 
Severe side effects, which may be very common (may affect more than 1 in 10 people), include:
Det anbefales at teste for proteinuri før start på behandling med MVASI. 
Testing for proteinuria is recommended prior to start of MVASI therapy.
Meget almindelige bivirkninger (kan påvirke flere end 1 patient ud af 10), som ikke var alvorlige, omfatter: 
Very common (may affect more than 1 in 10 people) side effects, which were not severe, include:
Studiet var designet som en åben, randomiseret, 2-armet fase III-evaluering af bevacizumab plus kemoterapi versus kemoterapi alene. 
This study was designed as an open-label, randomised, two-arm phase III evaluation of bevacizumab plus chemotherapy (CT + BV) versus chemotherapy alone (CT).
Behandling med bevacizumab 15 mg/kg hver 3. uge i kombination med kemoterapi (carboplatin og paclitaxel) i 6 og op til 8 behandlingsserier, efterfulgt af bevacizumab monoterapi indtil sygdomsprogression eller uacceptabel toksicitet, resulterede i en klinisk betydningsfuld og statistisk signifikant forbedring i samlet overlevelse sammenlignet med behandling med carboplatin og paclitaxel alene, ved data udledt fra eCRF. 
Treatment with bevacizumab at 15 mg/kg every 3 weeks in combination with chemotherapy (carboplatin and paclitaxel) for 6 and up to 8 cycles, followed by bevacizumab until disease progression or unacceptable toxicity resulted, when data were derived from eCRF, in a clinically meaningful and statistically significant improvement in OS compared to treatment with carboplatin and paclitaxel alone.
MVASI er, i kombination med erlotinib, indiceret til 1.linjebehandling hos voksne patienter med ikkeoperabel fremskreden, metastatisk eller recidiverende ikke-planocellulær, ikke-småcellet lungekræft med Epidermal Growth Factor Receptor (EGFR)-aktiverende mutationer (se pkt. 
MVASI, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).
Kongestivt hjertesvigta,b Supraventrikulær takykardi 
Congestive heart failurea,b, Supraventricular tachycardia
MVASI indeholder: 
What MVASI contains
Palmo-plantar erytrodysæstesisyndrom 
Palmar-plantar erythrodysaesthesi a syndrome
De eksploratoriske PFS- og OSanalyser af kemoterapi-kohorten (paclitaxel, topotecan og pegyleret liposomal doxorubicin) vises i tabel 
The exploratory PFS and OS analyses by chemotherapy cohort (paclitaxel, topotecan and PLD) are summarised in table 23.
• hul i galdeblæren (symptomer kan være mavesmerter, feber og kvalme/opkastning), 
• hole in the gall bladder (symptoms and signs may include abdominal pain, fever, and nausea/vomiting),
Bevacizumab kan påvirke sårhelingen negativt. 
Bevacizumab may adversely affect the wound healing process.